Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds were safe, well-tolerated, and demonstrated relevant clinical response, according to a press release.“These interim noninvasive data indicate that AXA1125 and AXA1957 are having a positive impact on multiple dysregulated biological pathways related to health and disease that are common in NAFLD [and nonalcoholic steatohepatitis] patients,” Stephen A. Harrison, MD, from Pinnacle Clinical Research in San Antonio, Texas, and principalRead More